 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Cidara Therapeutics
CDTX
conference date: August 13, 2024 press release only
Cidara Therapeutics Could Soar on Rezafungin Approval [Seeking Alpha, November 11, 2022]
Cidara Therapeutics: Rezafungin Data Could Bring Value [Seeking Alpha, July 20, 2021]
| 2024 | |||
| Cidara Therapeutics Q1 2024 Press Release | Cidara Therapeutics Q2 2024 Press Release | Cidara Therapeutics Q3 2024 Press Release | |
| May 15, 2024 | Aug. 13, 2024 | Nov. 7, 2024 | |
| 2023 | |||
| Cidara Therapeutics Q1 2023 Press Release | Cidara Therapeutics Q2 2023 Press Release | Cidara Therapeutics Q3 2023 Press Release | Cidara Therapeutics Q4 2023 Press Release |
| May 11, 2023 | Aug. 3, 2023 | Nov. 2, 2023 | April 23, 2024 |
| 2022 | |||
| Cidara Therapeutics Q1 2022 Press Release | Cidara Therapeutics Q2 2022 Press Release | Cidara Therapeutics Q3 2022 Press Release | Cidara Therapeutics Q4 2022 Press Release |
| May 11, 2022 | Aug. 9, 2022 | Nov. 3, 2022 | March 23, 2023 |
| 2021 | |||
| Cidara Therapeutics Q1 2021 Press Release | Cidara Therapeutics Q2 2021 Press Release | Cidara Therapeutics Q3 2021 Press Release | Cidara Therapeutics Q4 2021 Press Release |
| May 13, 2021 | Aug. 12, 2021 | Nov. 10, 2021 | March 7, 2022 |
Cidara Therapeutics (CDTX) is a clinical-stage biotechnology company specializing in therapies for viral and fungal infections.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers